🔓
Sign in as a Member to unlock the full view of HR.796. · Full carveout list, all affected companies, party defectors, and 30-day trade predictions.
Become a Member$24.50/mo already a Member? Sign in →
HR.796 · 119TH CONGRESS

Second Chance for Moms Act

Status
In Committee
Latest Action
2025-01-28
Sponsor
Miller, Mary E. (R-Illinois)
Official Source
Investability
35/100
Stage
COMMITTEE
Related Bills
0
Full Text
2,609 chars
Alive
Yes

What This Bill Does · Plain English

Summary · Congress.gov
Second Chance for Moms Act of 2025 This bill requires labeling of the drug mifepristone to include certain information about the hormone progesterone and establishes a related telephone hotline. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)

Action Timeline

2025-01-28
Referred to the House Committee on Energy and Commerce.
2025-01-28
Introduced in House
2025-01-28
Introduced in House

Frequently Asked Questions

Did HR.796 pass?
HR.796 is still alive. Current stage: COMMITTEE. Pass likelihood: 35%.
What does HR.796 do?
Second Chance for Moms Act of 2025 This bill requires labeling of the drug mifepristone to include certain information about the hormone progesterone and establishes a related telephone hotline. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
Who sponsored HR.796?
HR.796 was sponsored by Mary E. Miller (R-Illinois).

Full Bill Text

119 HR 796 IH: Second Chance for Moms Act U.S. House of Representatives 2025-01-28 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 119th CONGRESS 1st Session H. R. 796 IN THE HOUSE OF REPRESENTATIVES January 28, 2025 Mrs. Miller of Illinois (for herself, Mr. Babin , Mr. Moore of Alabama , Mr. Moore of West Virginia , Mr. Ogles , Mr. Webster of Florida , Ms. Tenney , Mr. Clyde , Mr. Harris of Maryland , and Mr. Weber of Texas ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to require a warning label advising that the effects of mifepristone can be counteracted, to amend the Public Health Service Act to establish a hotline to provide information to women seeking to counteract the effects of mifepristone, and for other purposes. 1. Short title This Act may be cited as the Second Chance for Moms Act of 2025 . 2. Mifepristone warning label and hotline (a) Warning label (1) In general Section 502 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 352 ) is amended by adding at the end the following: (hh) If it is the drug mifepristone, and its labeling does not bear the following statement printed in conspicuous text: WARNING: Medical evidence suggests that the abortifacient effects of mifepristone can be counteracted by natural progesterone, which can increase the chance of fetal survival. The American Society for Reproductive Medicine has determined that natural progesterone is safe in the first trimester of pregnancy. For more information, call [___]. (with the blank filled in to refer to the appropriate number for the hotline under section 1009 of the Public Health Service Act). . (2) Effective date Section 502(hh) of the Federal Food, Drug, and Cosmetic Act (as added by paragraph (1)) applies beginning on the date that is 6 months after the date of enactment of this Act. (b) Hotline Title X of the Public Health Service Act ( 42 U.S.C. 300 et seq. ) is amended by adding at the end the following: 1009. Hotline for reversal of effects of mifepristone (a) In general The Secretary shall establish or maintain, directly or by grant or contract, a toll-free hotline to provide support for 24 hours a day, 7 days a week, for women seeking to reverse the effects of the drug mifepristone. (b) Referrals to APR providers only A referral through the hotline described in subsection (a) may only be made to a health care provider that provides abortion pill reversal services. .
🔒 GovGreed Pro · Trading Intelligence on HR.796 Get Access — $24.50/mo
Loading intelligence layer…
Bill text sourced from GovInfo.gov · public domain · last updated 2026-09-14. Plain-English summary, score breakdown, and trading-intelligence panels are GovGreed-original analysis derived from STOCK Act filings, SEC Form 4 disclosures, FEC contributions, and Senate LDA lobbying reports — all publicly filed federal records. GovGreed is not affiliated with the U.S. Government. Not financial advice. [live render]